Luye Pharma’s Subsidiary Gets NMPA Green Light for Biosimilar Xgeva
Shandong Boan Biotechnology Co., Ltd (HKG: 6955), a controlling subsidiary of China-based Luye Pharma Group...
Blue Sail Medical Receives NMPA Approval for Disposable Coronary Intravascular Impact Waveguide
China’s Blue Sail Medical Co., Ltd (SHE: 002382) has announced that it has received marketing...
RareStone Group’s Pitolisant Secures NMPA Approval to Treat Narcolepsy in Children and Adolescents
RareStone Group, a China-based company specializing in rare diseases (formerly known as Citrine Medicine), has...
Sanofi’s Sarclisa Receives FDA Priority Review for Newly Diagnosed Multiple Myeloma Treatment
Sanofi plc (NYSE: SNY), a leading pharmaceutical company based in France, has announced that the...
Beijing Unveils Action Plan to Boost Pharmaceutical and Health Industry by 2026
The Beijing People’s Government has issued an “Action Plan” outlining measures and targets to “Accelerate...
Yantai Dongcheng Pharmaceutical Receives NMPA Approval for SSTR2 Targeted Radioactive Drug
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a pharmaceutical company based in China, has...
Medilink Therapeutics Partners with BioNTech to Develop ADC Products Using TMALIN Technology
Medilink Therapeutics, based in Suzhou, has entered into another partnership agreement with German biotechnology company...
Jiangsu Hengrui’s SHR-A1921 Anticipated to Gain NMPA Breakthrough Designation for Ovarian Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that its drug candidate SHR-A1921 is...
Chinese Biopharma Companies Set to Showcase Oncology Pipelines at ASCO 2024
A cohort of Chinese biopharmaceutical companies, including Wuhan YZY Biopharma Co., Ltd (HKG: 2496), Suzhou...
Novartis’ Fabhalta Shows Promise in Late-Stage C3 Glomerulopathy Trial
Novartis AG (NYSE: NVS), a leading Swiss pharmaceutical company, last week announced positive preliminary data...
Kexing Pharmaceutical Secures NMPA Approval for Childhood Growth Hormone Deficiency Study
Kexing Pharmaceutical (SHA: 688136), based in China, has received approval from the National Medical Products...
Henlius Biotech’s Denosumab Biosimilar Secures EMA Review for European Market Entry
Shanghai Henlius Biotech Inc. (HKG: 2696), a biopharmaceutical company based in China, has announced that...
Sihuan Pharma Halts Xuanzhu Biopharm’s IPO on Shanghai Sci-Tech Innovation Board
Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), a Chinese pharmaceutical company, has announced the cancellation...
Bayer’s Consumer Health Division to Invest $83 Million in New Supply Center in China
Bayer (ETR: BAYN)’s Consumer Health Division has entered into an agreement with Qidong city in...
Bio-Thera Solutions Receives NMPA Approval for BAT6005 and BAT1308 Combination Therapy Trial
Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it...
Boston Scientific Gets NMPA Approval for Agent DCB, First of Its Kind for Coronary ISR Treatment
Boston Scientific Corporation (NYSE: BSX), a leading medical device manufacturer in the U.S., has announced...
Eli Lilly Invests $5.3 Billion to Expand Manufacturing Capacity for Incretin Receptor Agonists
Eli Lilly and Company (NYSE: LLY) has announced a significant investment of USD 5.3 billion...
Novartis’ Atrasentan Shows Significant Reduction in Proteinuria in IgA Nephropathy Trial
Novartis AG (NYSE: NVS), a Swiss pharmaceutical company, last week presented interim results for the...
AccurEdit Therapeutics Publishes Positive Data for Gene-Edited Drug ART001 in Amyloidosis Treatment
AccurEdit Therapeutics (Suzhou) Co., Ltd., a leading gene editing therapy specialist based in China, has...
Shanghai Fosun Pharma’s FCN-159 File for Dendritic and Histiocytic Tumors Accepted by China’s NMPA
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that the National...